Form D · Biotechnology

Omniome, Inc.

San Diego, CA · CIK 0001608305

Offering snapshot reported Dec 11, 2019 · SEC filing

Reported sold
$60M
Offering amount: $60M
Investors reported
2
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 27, 2019
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 11, 2019Initial$60,000,003No comparison2SEC filing
Feb 26, 2019Initial$39,999,998No comparison9SEC filing
May 22, 2014Initial$225,000No comparison7SEC filing

Offering details

Securities
Equity, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-355241

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
N/ANone

Source: Form D, filed Dec 11, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Millard Y Chan Director, Executive
David Cruikshank Director
Kim Kamdar, Ph.D. Director
Catherine Lee Executive
David S. Mullarkey Director, Executive
John Murphy, Ph.D. Executive
Boris Nikolic, M.D. Director
Arnold Oliphant Executive
Kelly Perez Executive
Ken Song, M.D., Ph.D. Director, Executive
Kandaswamy Vijayan Director, Executive
Michael Yi Director
Dan Zabrowski Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
10275 Science Center Drive
San Diego, CA, 92121